The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blaser, C.
Right arrow Articles by Pircher, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blaser, C.
Right arrow Articles by Pircher, H.
The Journal of Immunology, 1998, 161: 6451-6454.
Copyright © 1998 by The American Association of Immunologists

CUTTING EDGE

Cutting Edge: Virus-Activated CD8 T Cells and Lymphokine-Activated NK Cells Express the Mast Cell Function-Associated Antigen, An Inhibitory C-Type Lectin1

Claudine Blaser, Martina Kaufmann and Hanspeter Pircher2

Institute for Medical Microbiology and Hygiene, Department of Immunology, University of Freiburg, Freiburg, Germany


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results and Discussion
 References
 
The mast cell function-associated Ag (MAFA) is an inhibitory C-type lectin that was originally identified on the cell surface of a rat mucosal mast cell line, RBL-2H3. We have cloned the mouse homologue of the rat MAFA gene, and Northern blot analysis revealed that mouse MAFA (mMAFA) gene expression was strongly induced in effector CD8 T cells and lymphokine-activated NK cells but not in effector CD4 T cells and in mouse mast cells. Moreover, mMAFA gene expression was only found in effector CD8 T cells that had been primed in vivo with live virus because in vitro activated CD8 T cells did not express mMAFA. Primary sequence comparison revealed a high degree of conservation (89% similarity) between rat MAFA and mMAFA. Thus, the MAFA molecule in the mouse is a putative inhibitory receptor on anti-viral CD8 T cells induced in vivo and on NK cells.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results and Discussion
 References
 
The mast cell secretory response is triggered by clustering of Fc{epsilon} receptors (Fc{epsilon}RI) by IgE immune complexes. A cell surface protein has been identified on the rat mucosal mast cell line RBL-2H3 that inhibits Fc{epsilon}RI-mediated degranulation and cytokine release after aggregation by a specific mAb (1). This molecule has been named mast cell function-associated antigen (MAFA),3 and molecular analysis revealed that MAFA is a type II membrane protein that belongs to the C-type lectin superfamily (2). MAFA exists as both a monomer and a disulfide-linked homodimer, and the intracellular domain contains a putative tyrosine-based inhibition motif that was found to be constitutively phosphorylated. These characteristics reveal a close relationship of MAFA with other members of the C-type lectin superfamily that function as inhibitory receptors (i.e., Ly49 and CD94/NKG2) in NK cells and also in T cells. However, MAFA expression in the rat analyzed with the sensitive RT-PCR technique has been reported to be mast cell specific (3).

We have used the "differential display" technique to identify genes in activated T cells, and in this context we have now cloned the mouse homologue of the rat MAFA gene. Surprisingly, we found that the MAFA gene in the mouse was strongly expressed both by effector CD8 T cells after priming in vivo by a viral infection and by lymphokine-activated NK cells. The present study represents the first characterization of this gene in the mouse; its product exhibits the molecular characteristics of a regulatory molecule for CD8-effector T cells.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results and Discussion
 References
 
Animals

C57BL/6 (B6) mice were purchased from Harlan Winkelmann (Borchen, Germany), and B6.PL-Thy1a (B6.Thy-1.1) mice were obtained from Dr. H. Mossmann (Max-Planck Institute for Immunobiology, Freiburg, Germany). CD8 lymphocytic choriomeningitis virus (LCMV) TCR transgenic mice (4) and CD4 LCMV TCR transgenic mice (5) were bred locally.

Viral strains

LCMV-WE was propagated on L929 cells, vesicular stomatitis virus (VSV) Indiana (Mudd-Summers isolate) was grown on baby hamster kidney cells and vaccinia virus (VV) strain WR was produced by infecting BSC 40 cells. Mice were infected i.v. with 200 plaque-forming units (PFU) of LCMV-WE, 106 PFU LCMV-docile, 2 x 106 PFU VSV, and 2 x 106 PFU VV WR.

Cell cultures and cell lines

T cells from CD8 LCMV TCR transgenic mice were stimulated weekly with LCMV-infected, irradiated (2500 rad) B6 peritoneal macrophages in Iscove’s modified Dulbecco’s medium (IMDM, Life Technologies, Paisley, U.K.) supplemented with 10% FCS and 20 U/ml IL-2 (PharMingen, San Diego, CA). CD8 memory T cells isolated from LCMV-immune B6 mice (4–6 wk after infection) were cultured and stimulated in the same manner. Bone marrow-derived mast cells were isolated from B6 mice as described (6) and stimulated for 8 h with 0.5 µM ionomycine (Sigma-Aldrich, Deisenhofen, Germany). To generate lymphokine-activated killer cells, B6 spleen cells (SC) were depleted after lysis of RBC from T and B cells by negative selection with Dynabeads (Dynal, Hamburg, Germany). The remaining cells were cultured for 6 days in IMDM supplemented with 10% FCS and 1000 U/ml IL-2. After 6 days, the cells (90–95% NK1.1+) were harvested.

Generation of effector and memory T cells

CD4 and CD8 effector and memory T cells were generated in vivo using an adoptive transfer system as described (7). Uninfected LCMVTCR transgenic mice were used as a source of naive CD4 or CD8 T cells. CD8 T cells were purified from SC by a two step negative selection procedure with Dynabeads as described (8). CD4-effector T cells were purified by depletion of CD8 T cells and B cells by negative selection with Dynabeads.

Differential display

The differential display analysis was performed as described (8) using the DELTA RNA Fingerprinting Kit (Clontech Laboratories, Palo Alto, CA). Full-length cDNA was obtained using long-distance RT-PCR and the SMART-PCR cDNA Synthesis Kit (Clontech) according to the manufacturer’s instructions.

Northern blot analysis

Total RNA was isolated from SC or purified cell populations with an RNA Isolation Kit (Fluka Chemie, Buchs, Switzerland). Northern blot analysis was performed as described (8) using 5–10 µg of total RNA per lane. The 600-bp fragment of the mouse MAFA (mMAFA) cDNA representing the entire coding region was used as mMAFA probe. The mouse cytoskeletal ß-actin probe (560 bp) was amplified from cDNA by PCR using 5' (ATGGATGACGATATCGCT) and 3' (ATGAGGTAGTCTGTCAGGT) primers.


   Results and Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
References
 
Identification of mMAFA

We performed mRNA differential display PCR to identify genes induced in effector CD8 T cells and isolated a PCR product that revealed significant sequence homology to the rat MAFA gene (2). Full-length cDNA was obtained by RT-PCR with mRNA from CD8 effector T cells and the full primary sequence was determined. The primary sequence was aligned with that of the rat MAFA, and sequence comparison revealed 80% identity and 89% similarity of the mouse to the rat sequence (Fig. 1Go). This result suggested that the mouse homologue of the rat MAFA gene had been isolated. Southern blot analysis of genomic DNA using a full-length mMAFA cDNA as a probe revealed a hybridization pattern suggesting that MAFA is a single gene in the mouse (not shown). The same conclusion has been drawn for the MAFA gene in the rat (3).



View larger version (30K):
[in this window]
[in a new window]
  		FIGURE 1. Amino acid sequence alignment of mouse and rat MAFA. Sequence numbering starts with the N terminus, which is located in the cytoplasma. The putative immunoreceptor tyrosine-based inhibition motif is shown in bold and the putative transmembrane region is underlined. The complete nucleotide sequence of mMAFA is available from the EMBL database under accession number AJ010751.

 
mMAFA is induced in CD8 but not in CD4 T cells after LCMV infection

Northern blot analysis using the mMAFA cDNA as a probe demonstrated that CD8 T cells from LCMV TCR transgenic mice isolated on both day 8 and day 14 after LCMV infection expressed high levels of mMAFA mRNA (Fig. 2GoA, lanes 2 and 3). In contrast, naive CD8 T cells from these mice did not express mMAFA at detectable levels (Fig. 2GoA, lane 1). In CD8 memory T cells, mMAFA gene expression was still detectable 3–4 wk after infection, but to a lower extent (Fig. 2GoA, lanes 4 and 5). Importantly, mMAFA gene expression was also induced in CD8 effector T cells from normal C57BL/6 mice isolated 8 days after LCMV infection (Fig. 2GoB, lane 2). To test whether SC other than CD8 effector T cells expressed mMAFA, SC from B6 mice taken on day 8 after LCMV infection were depleted of CD8 T cells by negative selection in vitro. As shown in Fig. 2GoB, lane 3, these CD8-depleted immune SC did not express mMAFA at significant levels, indicating that mMAFA was virtually exclusively expressed in activated CD8 T cells. To directly compare mMAFA expression in activated CD4 and CD8 T cells, effector T cells were generated using CD4 and CD8 TCR transgenic mice, which both express an Ag receptor specific for LCMV glycoprotein (GP). T cells from CD8 LCMV TCR transgenic mice are specific for LCMV GP amino acid 33–41 in the context of H-2Db (4), and CD4 LCMV TCR transgenic mice express an Ag receptor specific for LCMV GP amino acid 61–80 together with I-Ab (5). CD4 and CD8 T cells from both TCR transgenic lines were activated in vivo using the same adoptive transfer system, which allows the same vigorous expansion of the transferred transgenic T cells (5, 7). As shown in Fig. 2GoB, lane 5, effector cells from CD4 LCMV TCR transgenic mice expressed mMAFA at low levels when compared with effector cells from CD8 LCMV TCR transgenic mice (lane 4). Thus, these results indicated that mMAFA expression on effector T cells was CD8 specific.



View larger version (37K):
[in this window]
[in a new window]
  		FIGURE 2. A, Northern blot analysis of mMAFA expression in CD8 T cells from CD8 LCMV TCR transgenic mice isolated at the indicated time points after LCMV infection. Lane 1, Naive CD8 T cells. Lanes 2–5, Effector/memory CD8 T cells isolated on day 8 (lane 2), day 14 (lane 3), day 21 (lane 4), and day 28 (lane 5) after infection. B, Northern blot analysis of mMAFA expression in B6 SC and in CD4 and CD8 LCMV TCR transgenic cells after LCMV infection. Lane 1, SC from naive B6 mice. Lane 2, SC from day 8 LCMV-immune B6 mice. Lane 3, CD8 T cell-depleted SC from day 8 LCMV-immune B6 mice. Lane 4, CD8 LCMV TCR transgenic effector cells isolated 8 days after LCMV infection. Lane 5, CD4 LCMV TCR transgenic effector cells isolated 8 days after LCMV infection. For each lane, 10 µg of total RNA were loaded. Equivalent sample loading was assured by hybridization with a ß-actin probe.

 
Induction of mMAFA expression in CD8 T cells is not restricted to LCMV infection but requires in vivo priming with virus

To examine whether viral infections other than LCMV were also capable of inducing mMAFA expression, SC from B6 mice acutely infected with LCMV, VV, or VSV were examined. Fig. 3GoA shows that mMAFA expression levels were comparable in splenocytes from mice infected with either LCMV, VSV, or VV. It is noteworthy that mMAFA expression was lower in splenocytes from mice infected with a high dose (106 PFU) of the docile strain of LCMV, a virus strain known to induce clonal exhaustion of CD8 effector T cells (9). To test whether Ag stimulation in vitro also induced mMAFA expression, CD8 T cells from LCMV TCR transgenic mice were stimulated with LCMV-infected APC. Ag stimulation of CD8 T cells from LCMV TCR transgenic mice in vitro is known to lead to vigorous proliferation and induction of CTL activity (10). However, these in vitro conditions were not sufficient to induce significant mMAFA expression (Fig. 3GoB, lanes 2–4). Only after repeated restimulation and prolonged in vitro culture (3–4 wk), low level mMAFA expression was apparent in these cultures (Fig. 3GoB, lanes 5 and 6). In striking contrast, high levels of mMAFA expression were induced in memory CD8 T cells within 3 days of in vitro restimulation (Fig. 3GoB, lane 7); these memory CD8 T cells had been primed in vivo with LCMV.



View larger version (54K):
[in this window]
[in a new window]
  		FIGURE 3. A, Northern blot analysis of mMAFA expression in the spleen of B6 mice after the viral infections indicated. Lane 1, SC from naive B6 mice. Lane 2, SC from day 8 LCMV-WE-immune mice. Lane 3, SC from day 8 LCMV-docile-immune mice. Lane 4, SC from day 6 VSVIND-immune mice. Lane 5, SC from day 6 VV-immune mice. The docile strain of LCMV exhibited a decreased capacity to induce CD8 effector T cells (9). B, Northern blot analysis of mMAFA expression in in vitro stimulated CD8 T cells from CD8 LCMV TCR transgenic mice. Naive CD8 T cells from LCMV TCR transgenic mice (lane 1) were stimulated once a week with LCMV-infected macrophages, and CD8 T cells were harvested from the culture on the days indicated (lanes 2–6). Lane 7, CD8 T cells from LCMV memory (memo) mice were restimulated for 3 days in vitro with LCMV-infected macrophages. For each lane, 10 µg of total RNA were loaded; hybridization with a ß-actin probe shows constant sample loading.

 
mMAFA expression occurs in NK but not in mast cells

Expression of mMAFA mRNA was not detected by Northern blotting in brain, heart, kidney, liver, lymph node, lung, skeletal muscle, spleen, thymus, and testis (not shown). As depicted in Fig. 4GoA, mMAFA was also not expressed in EL-4, RMA-S, BW5147 lymphoma cells, or in CD4 and CD8 T-cell hybridomas (BWLy2–3, IT H6/A11). Similarly, J558 and P3-X63Ag8 myeloma cells and B cell hybridomas did not express mMAFA. However, the CTL clone HY-Ad9 (Fig. 4GoA, lane 3), which exhibits NK-like activity (11), expressed mMAFA levels comparable to CD8-effector T cells. This result led us to examine mMAFA expression in lymphokine-activated NK1.1+ killer cells. As shown in Fig. 4GoB, lane 3, lymphokine-activated NK1.1+ cells (95% purity) generated by culturing T and B cell-depleted SC in the presence of IL-2 expressed high levels of mMAFA mRNA. The expression pattern of mMAFA is reminiscent of KIR and CD94/NKG2 molecules, which function as inhibitory receptors for both human NK cells (12, 13) and T cells (14, 15, 16). Similar to our data with mMAFA, KIRs are expressed on NK cells and on effector/memory phenotype CD8 T cells (17), and attempts to induce KIR expression on T cells by in vitro stimulation were unsuccessful (17, 18).



View larger version (34K):
[in this window]
[in a new window]
  		FIGURE 4. Northern blot analysis of mMAFA expression. A, Expression in lymphomas (EL-4, RMA-S, BW 5147), cloned CTLs (CTLL-2, HY-Ad9), T cell hybridomas (BWLy2–3, IT H6/A11), myelomas (J558, P3-X63Ag8), and B cell hybridomas (B22.249, T21-4.60, B8-24-3). B, mMAFA expression in lymphokine-activated NK1.1+ cells. Lane 1, SC from naive B6 mice. Lane 2, SC from day 8 LCMV immune B6 mice. Lane 3, NK 1.1+ lymphokine-activated killer cells from B6 mice. C, mMAFA expression in bone marrow-derived mast cells (BM-mast cells). Lane 1, SC from day 8 LCMV-immune B6 mice. Lane 2, BM-mast cell culture isolated from B6 mice. Lane 3, Ionomycine-treated BM-mast cell culture. For each lane, 10 µg of total RNA were loaded; constant sample loading was controlled by hybridization with a ß-actin probe.

 
The MAFA gene was originally identified in the rat mucosal mast cell line RBL-2H3, and, in the rat, MAFA gene expression appears to be mast cell specific because signals were obtained from lung tissue but not from other organs including spleen and lymph nodes when the sensitive RT-PCR technique was used (3). Surprisingly, we did not observe mMAFA gene expression in IL-3/IL-4 induced bone marrow-derived mast cell cultures, which are thought to represent an in vitro analogue of mucosal mast cells (6) (Fig. 4GoC, lane 2). In addition, stimulation of these cells with ionomycine did not lead to mMAFA gene expression (Fig. 4GoC, lane 3). Our results indicate that MAFA gene expression in the mouse is not mast cell specific and may not even be expressed on mucosal mast cells in this species.

In analogy to the inhibitory effect on mast cell degranulation by rat MAFA, we postulate that the mouse homologue has a similar function and serves as an inhibitory molecule on CD8-effector T cells and on NK cells. Due to the lack of the appropriate serological reagents, we could not yet test this hypothesis directly. However, it is important to stress that the inhibitory function of the rat MAFA molecule has been clearly established (1). In contrast to rat MAFA, which is constitutively expressed in the rat mast cell line RBL-2H3, mMAFA expression in CD8 T cells was induced by Ag stimulation. Compared with other T cell-activation markers, mMAFA appears rather late in the course of a CTL response. This late kinetic of mMAFA expression fits in well with the postulated inhibitory role of this molecule for CD8 effector T cells.


   Acknowledgments
 
We thank Dr. A. Oxenius for the generous gift of CD4 LCMV TCR transgenic mice and Dr. E. Schmitt for the mast cell cultures. We also thank S. Batsford for comments on the manuscript and S. Denkler and T. Imhof for animal husbandry.


   Footnotes
 
1 This work was supported by the State of Baden-Württemberg (Zentrum für Klinische Forschung I/Universitätsklinikum Freiburg) and by the Deutsche Forschungsgemeinschaft (Pi-295/1-2). Back

2 Address correspondence and reprint requests to Dr. Hanspeter Pircher, Institute for Medical Microbiology and Hygiene, Department of Immunology, Hermann-Herder-Strasse 11, University of Freiburg, D-79104 Freiburg, Germany. E-mail address: Back

3 Abbreviations used in this paper: MAFA, mast cell function-associated Ag; mMAFA, mouse MAFA; LCMV, lymphocytic choriomeningitis virus; VSV, vesicular stomatitis virus; SC, spleen cells; PFU, plaque-forming unit; VV, vaccinia virus; GP, glycoprotein. Back

Received for publication August 27, 1998. Accepted for publication October 13, 1998.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 

  1. Soto, E. O., I. Pecht. 1988. A monoclonal antibody that inhibits secretion from rat basophilic leukemia cells and binds to a novel membrane component. J. Immunol. 141:4324.[Abstract]
  2. Guthmann, M. D., M. Tal, I. Pecht. 1995. A secretion inhibitory signal transduction molecule on mast cells is another C-type lectin. Proc. Natl. Acad. Sci. USA 92:9397.[Abstract/Free Full Text]
  3. Bocek, P., M. D. Guthmann, I. Pecht. 1997. Analysis of the genes encoding the mast cell function-associated antigen and its alternatively spliced transcripts. J. Immunol. 158:3235.[Abstract]
  4. Pircher, H., K. Bürki, R. Lang, H. Hengartner, R. M. Zinkernagel. 1989. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 342:559.[Medline]
  5. Oxenius, A., M. F. Bachmann, R. M. Zinkernagel, H. Hengartner. 1998. Virus-specific MHC-class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection. Eur. J. Immunol. 28:390.[Medline]
  6. Huels, C., T. Germann, S. Goedert, P. Hoehn, S. Koelsch, L. Hultner, N. Palm, E. Rude, E. Schmitt. 1995. Co-activation of naive CD4+ T cells and bone marrow-derived mast cells results in the development of Th2 cells. Int. Immunol. 7:525.[Abstract/Free Full Text]
  7. Zimmermann, C., K. Brduscha-Riem, C. Blaser, R. M. Zinkernagel, H. Pircher. 1996. Visualization, characterization and turnover of CD8+ memory T cells in virus-infected hosts. J. Exp. Med. 183:1367.[Abstract/Free Full Text]
  8. Blaser, C., M. Kaufmann, C. Müller, C. Zimmermann, V. Wells, L. Mallucci, H. Pircher. 1998. ß-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. Eur. J. Immunol. 28:1.[Medline]
  9. Moskophidis, D., F. Lechner, H. P. Pircher, R. M. Zinkernagel. 1993. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362:758.[Medline]
  10. Kyburz, D., P. Aichele, D. E. Speiser, H. Hengartner, R. Zinkernagel, H. Pircher. 1993. T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides. Eur. J. Immunol. 23:1956.[Medline]
  11. Acha-Orbea, H., P. Groscurth, R. Lang, L. Stitz, H. Hengartner. 1983. Characterization of cloned cytotoxic lymphocytes with NK-like activity. J. Immunol. 130:2952.[Abstract]
  12. Lanier, L. L.. 1997. Natural killer cells: from no receptors to too many. Immunity 6:371.[Medline]
  13. Moretta, A., L. Moretta. 1997. HLA class I specific inhibitory receptors. Curr. Opin. Immunol. 9:694.[Medline]
  14. Phillips, J. H., J. E. Gumperz, P. Parham, L. L. Lanier. 1995. Superantigen-dependent, cell-mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes. Science 268:403.[Abstract/Free Full Text]
  15. Mingari, M. C., C. Vitale, A. Cambiaggi, F. Schiavetti, G. Melioli, S. Ferrini, A. Poggi. 1995. Cytolytic T lymphocytes displaying natural killer (NK)-like activity: expression of NK-related functional receptors for HLA class I molecules (p58 and CD94) and inhibitory effect on the TCR-mediated target cell lysis of lymphokine production. Int. Immunol. 7:697.[Abstract/Free Full Text]
  16. De Maria, A., A. Ferraris, M. Guastella, S. Pilia, C. Cantoni, L. Polero, M. C. Mingari, D. Bassetti, A. S. Fauci, L. Moretta. 1997. Expression of HLA class I-specific inhibitory natural killer cell receptors in HIV-specific cytolytic T lymphocytes: impairment of specific cytolytic functions. Proc. Natl. Acad. Sci. USA 94:10285.[Abstract/Free Full Text]
  17. Mingari, M. C., A. Moretta, L. Moretta. 1998. Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. Immunol. Today 19:153.[Medline]
  18. D‘Andrea, A., L. L. Lanier. 1998. Killer cell inhibitory receptor expression by T cells. Curr. Top. Microbiol. Immunol. 230:25.[Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
S. Schwartzkopff, C. Grundemann, O. Schweier, S. Rosshart, K. E. Karjalainen, K.-F. Becker, and H. Pircher
Tumor-Associated E-Cadherin Mutations Affect Binding to the Killer Cell Lectin-Like Receptor G1 in Humans
J. Immunol., July 15, 2007; 179(2): 1022 - 1029.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. D. Huntington, H. Tabarias, K. Fairfax, J. Brady, Y. Hayakawa, M. A. Degli-Esposti, M. J. Smyth, D. M. Tarlinton, and S. L. Nutt
NK Cell Maturation and Peripheral Homeostasis Is Associated with KLRG1 Up-Regulation
J. Immunol., April 15, 2007; 178(8): 4764 - 4770.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
M. S. Tessmer, C. Fugere, F. Stevenaert, O. V. Naidenko, H. J. Chong, G. Leclercq, and L. Brossay
KLRG1 binds cadherins and preferentially associates with SHIP-1
Int. Immunol., April 1, 2007; 19(4): 391 - 400.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. H. Vesper, L. T. Raetzman, and S. A. Camper
Role of Prophet of Pit1 (PROP1) in Gonadotrope Differentiation and Puberty
Endocrinology, April 1, 2006; 147(4): 1654 - 1663.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
M. Ito, T. Maruyama, N. Saito, S. Koganei, K. Yamamoto, and N. Matsumoto
Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity
J. Exp. Med., February 21, 2006; 203(2): 289 - 295.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
M. Colonna
Cytolytic responses: cadherins put out the fire
J. Exp. Med., February 20, 2006; 203(2): 261 - 264.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Grundemann, M. Bauer, O. Schweier, N. von Oppen, U. Lassing, P. Saudan, K.-F. Becker, K. Karp, T. Hanke, M. F. Bachmann, et al.
Cutting Edge: Identification of E-Cadherin as a Ligand for the Murine Killer Cell Lectin-Like Receptor G1
J. Immunol., February 1, 2006; 176(3): 1311 - 1315.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
R. Thimme, V. Appay, M. Koschella, E. Panther, E. Roth, A. D. Hislop, A. B. Rickinson, S. L. Rowland-Jones, H. E. Blum, and H. Pircher
Increased Expression of the NK Cell Receptor KLRG1 by Virus-Specific CD8 T Cells during Persistent Antigen Stimulation
J. Virol., September 15, 2005; 79(18): 12112 - 12116.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
M. Eberl, R. Engel, S. Aberle, P. Fisch, H. Jomaa, and H. Pircher
Human V{gamma}9/V{delta}2 effector memory T cells express the killer cell lectin-like receptor G1 (KLRG1)
J. Leukoc. Biol., January 1, 2005; 77(1): 67 - 70.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. H. Robbins, M. S. Tessmer, T. Mikayama, and L. Brossay
Expansion and Contraction of the NK Cell Compartment in Response to Murine Cytomegalovirus Infection
J. Immunol., July 1, 2004; 173(1): 259 - 266.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. H. Robbins, S. C. Terrizzi, B. C. Sydora, T. Mikayama, and L. Brossay
Differential Regulation of Killer Cell Lectin-Like Receptor G1 Expression on T Cells
J. Immunol., June 15, 2003; 170(12): 5876 - 5885.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Voehringer, M. Koschella, and H. Pircher
Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1)
Blood, November 15, 2002; 100(10): 3698 - 3702.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. W. McMahon, A. J. Zajac, A. M. Jamieson, L. Corral, G. E. Hammer, R. Ahmed, and D. H. Raulet
Viral and Bacterial Infections Induce Expression of Multiple NK Cell Receptors in Responding CD8+ T Cells
J. Immunol., August 1, 2002; 169(3): 1444 - 1452.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. H. Robbins, K. B. Nguyen, N. Takahashi, T. Mikayama, C. A. Biron, and L. Brossay
Cutting Edge: Inhibitory Functions of the Killer Cell Lectin-Like Receptor G1 Molecule During the Activation of Mouse NK Cells
J. Immunol., March 15, 2002; 168(6): 2585 - 2589.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. Xu, J. Abramson, M. Fridkin, and I. Pecht
SH2 Domain-Containing Inositol Polyphosphate 5'-Phosphatase Is the Main Mediator of the Inhibitory Action of the Mast Cell Function-Associated Antigen
J. Immunol., December 1, 2001; 167(11): 6394 - 6402.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. Voehringer, C. Blaser, P. Brawand, D. H. Raulet, T. Hanke, and H. Pircher
Viral Infections Induce Abundant Numbers of Senescent CD8 T Cells
J. Immunol., November 1, 2001; 167(9): 4838 - 4843.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blaser, C.
Right arrow Articles by Pircher, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blaser, C.
Right arrow Articles by Pircher, H.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS